Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-Arm Phase 2 Study of Valemetostat Tosylate in Relapsed/Refractory Peripheral T-Cell Lymphoma
2020-004954-31Phase 2Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of valemetostat in peripheral T-cell lymphoma (PTCL), adult T-cell leukemia-lymphoma (ATLL) and lymphoma (2 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective Response Rate (ORR). Started Apr 2021; status: active.
02
Drugs
valemetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)adult T-cell leukemia-lymphoma (ATLL)lymphoma
Beyond the preview
Go deeper on 2020-004954-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004954-31.